Microneedles for treatment of peanut allergy

微针治疗花生过敏

• 批准号: 10471226
• 负责人: Harvinder Singh Gill
• 金额: $ 63.27万
• 依托单位: TEXAS TECH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-17 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10471226
• 关键词: Adverse effects; Allergen Immunotherapy; Allergens; Allergic Disease; Allergy Shot; Allergy to peanuts; Anaphylaxis; Anatomy; Animals; Antibodies; Antigens; Area; Attention; Autoimmune Diseases; Behavior; Biomedical Engineering; Body Weight decreased; Bone Marrow; Child; Clinic; Clinical Trials; Cutaneous; Data; Deposition; Development; Diarrhea; Diet; Dose; Effectiveness; Ensure; Erythema; Exhibits; Exposure to; FDA approved; Family; Family suidae; Food; Food Hypersensitivity; Foundations; Generations; Gills; Goals; Hemorrhage; Histologic; Human; Hypersensitivity; IgG4; Immune; Immune response; Immunoglobulin G; Immunoglobulin-Secreting Cells; Immunology; Immunotherapy; Intestines; Langerhans cell; Lead; Length; Life; Life Style; Malnutrition; Medicine; Modeling; Mus; Neonatal; Oral; Passive Immunization; Patients; Pediatric Hospitals; Personal Satisfaction; Persons; Phase; Phenotype; Physiology; Plasma Cells; Play; Population; Production; Regulatory T-Lymphocyte; Research; Respiratory distress; Risk; Role; Safety; Skin; Stress; Technology; Texas; Therapeutic Effect; Treatment Efficacy; acute symptom; base; biological adaptation to stress; comparative; desensitization; design; environmental allergy; immunogenicity; in vivo; milligram; mouse model; novel; oral immunotherapy; porcine model; prevent; programs; side effect; success; therapeutic effectiveness; uptake; vaccinology

Microneedles for treatment of peanut allergy Peanut allergy is a life-threatening condition. About 1% of the US population (~3 million people) has peanut allergies, and there is no FDA-approved treatment. Strict avoidance, and a peanut-free diet is the only option available to manage peanut allergies, which imposes severe limitations on the lifestyle of the patient and their families, and can lead to nutritional deficiencies. The overall goal of this proposal is to develop a coated microneedles (MNs) based cutaneous immunotherapy (CIT) a.k.a (MNs-CIT) for peanut allergy. Presently peanut oral immunotherapy has received much attention. However, a major limitation of oral immunotherapy is that the peanut oral dose is escalated to thousands of milligrams, which causes adverse effects. Based on our preliminary data our hypothesis is that MNs coated with peanut allergen can safely deliver peanut allergen in to the superficial skin-layer to produce long-lasting peanut desensitization. Our specific aims are: (i) Develop PE- coated MNs and evaluate their short and long term therapeutic effectiveness in treating peanut allergy, (ii) Characterize the mechanism of peanut MNs-CIT, and (iii) Evaluate therapeutic efficacy in a neonatal pig model of peanut allergy. If successful, these studies will provide the foundation to support the development of a novel and safer peanut allergy immunotherapy treatment.

微针治疗花生过敏 花生过敏是一种危及生命的疾病。约 1% 的美国人口（约 300 万人）食用花生 过敏，并且没有 FDA 批准的治疗方法。严格避免，无花生饮食是唯一选择 可用于控制花生过敏，这严重限制了患者及其家人的生活方式 家庭，并可能导致营养缺乏。该提案的总体目标是开发一种涂层 基于微针（MNs）的皮肤免疫疗法（CIT）又名（MNs-CIT）治疗花生过敏。目前 花生口服免疫疗法备受关注。然而，口服免疫疗法的一个主要限制是 花生口服剂量增加到数千毫克，会产生不良影响。基于我们的 初步数据我们的假设是，涂有花生过敏原的 MN 可以安全地将花生过敏原传递到 浅表皮肤层产生持久的花生脱敏作用。我们的具体目标是： (i) 发展 PE- 涂覆微球并评估其治疗花生过敏的短期和长期治疗效果，(ii) 表征花生 MNs-CIT 的机制，以及 (iii) 评估新生猪模型的治疗效果 花生过敏。 如果成功，这些研究将为支持新型、更安全的花生的开发奠定基础 过敏免疫疗法治疗。

项目成果

Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut.

皮肤内的靶向过敏原特异性免疫疗法可改善过敏原的传递，从而诱导对花生的脱敏。

• DOI: 10.2217/imt-2021-0206
• 发表时间: 2022
• 期刊: Immunotherapy
• 影响因子: 2.8
• 作者: Landers,JeffreyJ;Janczak,KatarzynaW;Shakya,AkhileshKumar;Zarnitsyn,Vladimir;Patel,SamirkumarR;BakerJr,JamesR;Gill,HarvinderSingh;O'Konek,JessicaJ
• 通讯作者: O'Konek,JessicaJ